{"schema_version":"secwatch.filing_event.v1","accession":"0001193125-26-202506","form_type":"8-K","ticker":"AXSM","cik":"0001579428","company_name":"Axsome Therapeutics, Inc.","filed_at":"2026-05-04T23:59:59+00:00","discovered_at":"2026-05-14T18:02:32.507145+00:00","generated_at":"2026-05-14T23:54:29.806307+00:00","sec_items":["2.02","8.01","9.01"],"event_type":"earnings","sentiment":"positive","materiality_score":0.85,"calibrated_materiality_score":0.85,"confidence":"high","headline":"Axsome Q1 revenue $191.2M (+57% YoY); Auvelity approved for Alzheimer's agitation","bullets":["Total net product revenue $191.2M (+57% YoY); Auvelity $153.2M (+59%), Sunosi $33.9M (+34%), Symbravo $4.1M.","Net loss $64.5M ($1.26/share) vs $59.4M ($1.22/share) YoY; cash $305.1M at March 31, 2026.","FDA approved Auvelity for agitation in Alzheimer's disease (April 2026); full commercial launch expected June 2026.","NDA submitted for AXS-12 (cataplexy in narcolepsy); pipeline expanded with AXS-20 (balipodect) for schizophrenia/Tourette.","Cash guidance: current resources sufficient to fund operations into cash flow positivity."],"urls":{"canonical":"https://secwatch.observer/filing/0001193125-26-202506","json":"https://secwatch.observer/filing/0001193125-26-202506.json","markdown":"https://secwatch.observer/filing/0001193125-26-202506.md","text":"https://secwatch.observer/filing/0001193125-26-202506.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1579428/000119312526202506/0001193125-26-202506-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1579428/000119312526202506/axsm-20260504.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-05-14T23:54:29.806307+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[{"claim_id":"2d9524a1b14487391651028d70a5148d2b7e7ab6","claim":"Axsome Therapeutics, Inc. reported first quarter of 2026 results: revenue $191.2 million, net income $(64.5) million, EPS $(1.26) per share.","evidence_excerpt":"Total net product revenue was $191.2 million for the first quarter of 2026, representing 57% year-over-year growth.","evidence_source":"SEC 8-K Item 2.02","evidence_url":"https://www.sec.gov/Archives/edgar/data/1579428/000119312526202506/0001193125-26-202506-index.htm","confidence":0.95,"family_label":"Earnings Releases","details":[{"label":"Period","value":"first quarter of 2026"},{"label":"Revenue","value":"$191.2 million"},{"label":"Net income","value":"$(64.5) million"},{"label":"EPS","value":"$(1.26) per share"},{"label":"Result","value":"reported results"}]}],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}